





























Link to publication record in King's Research Portal
Citation for published version (APA):
Sipos, O., Tovey, H., Quist, J., Hyder, S., Nowinski, S., Gazinska, P., Kernaghan, S., Toms, C., Maguire, S., Orr,
N., Linn, S., Owen, J., Gillett, C., Pinder, S., Bliss, J., Tutt, A., Cheang, M. C. U., & Grigoriadis, A. (2021).
Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple
negative breast cancer: the TNT trial. Annals of Oncology, 32(1), 58-65.
https://doi.org/10.1016/j.annonc.2020.10.475
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 20. Apr. 2021
 1 
Original article 1 
Assessment of structural chromosomal instability phenotypes as 2 
biomarkers of carboplatin response in the TNT trial 3 
 4 
O. Sipos1, H. Tovey2, J. Quist3, 4, S. Haider1, S. Nowinski4, P. Gazinska1, S. Kernaghan2, C. 5 
Toms2, S. Maguire1, N. Orr1, S. C. Linn5, J. Owen6, C. Gillett6, S. E. Pinder4, J. M. Bliss2, A. 6 
Tutt1, 3, 4, M. C. U. Cheang2, A. Grigoriadis3, 4 * 7 
 8 
* Corresponding author:  9 
Dr. Anita Grigoriadis, Breast Cancer Now Unit, Innovation Hub, Cancer Centre at Guy’s, 10 
Great Maze Pond, London, SE1 9RT, UK 11 
phone: +44 020 7188 2360 12 




1 Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, 17 
London, UK 18 
 19 
2 Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK  20 
3 Breast Cancer Now Unit, King's College London Faculty of Life Sciences and Medicine, 21 
London, UK 22 
 23 
4 School of Cancer & Pharmaceutical Sciences, King's College London Faculty of Life Sciences 24 
and Medicine, London, UK  25 
 26 
5 Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands 27 
6 King's Health Partners Cancer Biobank, London, UK 28 






In the TNT trial (NCT00532727) germline BRCA1/2 mutations were present in 28% of 34 
carboplatin responders. We assessed quantitative measures of structural chromosomal 35 
instability (CIN) to identify a wider patient subgroup within TNT with preferential benefit 36 
from carboplatin over docetaxel. 37 
 38 
Patients and methods 39 
 40 
Copy number aberrations (CNAs) were established from 135 FFPE primary carcinomas using 41 
Illumina OmniExpress SNP-arrays. Seven published (allelic imbalanced CNA, AiCNA; allelic 42 
balanced CNA, AbCNA; copy number neutral loss of heterozygosity, CnLOH; number of 43 
telomeric allelic imbalances, NtAI; BRCA1-like status; percentage of genome altered, PGA; 44 
homologous recombination deficiency, HRD scores) and two novel (Shannon index, SI; high-45 
level amplifications, HLAMP) CIN-measurements were derived. HLAMP was defined based 46 
on the presence of at least 1 of the top 5% amplified cytobands located on 1q, 8q and 10p. 47 
Continuous CIN-measurements were divided into tertiles. All nine CIN-measurements were 48 




Patients with tumours without HLAMP had a numerically higher ORR and significantly longer 53 
PFS in the carboplatin(C) than in the docetaxel(D) arm (56%(C) versus 29%(D), 54 
PHLAMP,quiet=0.085; 6.1 months(C) vs 4.1 months(D), Pinteraction/HLAMP= 0.047). In the carboplatin 55 
arm, patients with tumours showing intermediate telomeric NtAI and AiCNA had higher ORR 56 
(54%(C) versus 20%(D), PNtAI,intermediate=0.03; 62%(C) versus 33%(D), PAiCNA,intermediate=0.076). 57 
Patients with high AiCNA and PGA had shorter PFS in the carboplatin arm (3.4 months (high) 58 
versus 5.7 months (low/intermediate); and 3.8 months (high) versus 5.6 months 59 
(low/intermediate), respectively; Pinteraction/AiCNA=0.027, Padj.interaction/AiCNA=0.125 and 60 
Pinteraction/PGA=0.053, Padj.interaction/PGA=0.176), whilst no difference was observed in the 61 




Patients with tumours lacking HLAMP and demonstrating intermediate CIN-measurements 66 
formed a subgroup benefitting from carboplatin relative to docetaxel treatment within the 67 
TNT trial. This suggests a complex and paradoxical relationship between the extent of 68 
genomic instability in primary tumours and treatment response in the metastatic setting. 69 
 70 
Keywords: metastatic triple negative breast cancer, carboplatin, genomic instability, allelic 71 
imbalance 72 
 73 




• Patients with intermediate levels of allelic imbalanced CNAs show a better response 77 
rate to carboplatin in TNT 78 
• The lack of amplifications on 1q, 8q and 10p is associated with a superior carboplatin 79 
response in TNT 80 
• The relation between chromosomal instability in primary tumours and carboplatin 81 




The TNT trial (NCT00532727), a phase III, open label, randomised clinical trial compared 85 
carboplatin (C) to docetaxel (D) in patients with recurrent locally advanced or metastatic 86 
triple negative breast cancer (TNBC) or with recurrent locally advanced or metastatic 87 
disease in germline BRCA1/2 mutation carriers irrespective of ER/PR/HER2 status. TNT trial 88 
patients with germline BRCA1/2 mutations had a significantly better objective response rate 89 
(ORR) to carboplatin and showed improved progression free survival (PFS) with this agent1. 90 
As some TNBC patients without known germline defects of BRCA1/2 benefit from platinum-91 
based chemotherapy, biomarkers that better predict treatment response for this subgroup 92 
of patients are urgently required2, 3. 93 
 94 
Most TNBCs display highly aberrant genomes as a consequence of defects in DNA Damage 95 
Response (DDR) pathways. In ~35% of TNBCs, this increased genomic instability can be 96 
explained by functional inactivation of BRCA1/23, leading to homologous recombination 97 
deficiency (HRD)4. Using a range of platforms, including array comparative genomic 98 
hybridisation (aCGH)5, SNP arrays6-9, targeted sequencing panels10-12 and whole genome 99 
sequencing3, 10, 12, 13, measures of unique patterns of chromosomal instability (CIN) have 100 
been developed to identify “BRCAness”14 and HRD, which potentially identify sensitivity to 101 
DDR-targeting drugs compared to other standards of care. Such measures are sometimes 102 
referred to as “genomic scars” and include mutational and rearrangement signatures. In the 103 
neoadjuvant setting, these “genomic scars” have been shown to carry clinically relevant 104 
information for platinum-based chemotherapy response in TNBC patients2, 9, 11. However, 105 
their value for patients with advanced disease is still debatable. High levels of HRD were 106 
associated with platinum response in the single agent platinum TBCR009 study15, whilst the 107 
Myriad HRD score2 was not specifically associated with improved carboplatin ORR or PFS 108 
compared to docetaxel in the TNT trial1. 109 
 110 
Here, we have quantitatively assessed a suite of nine CIN-measurements based on genome 111 
profiles of primary tumours from the TNT trial to identify a wider patient subgroup 112 
benefitting from carboplatin over docetaxel. We compared their prevalence to the patient’s 113 
pathogenic germline and somatic BRCA1/2 mutation and BRCA1 promoter methylation 114 
status. Then, we asked whether a primary tumour’s degree of genomic instability has 115 
predictive value with regards to treatment response of the metastatic disease, and whether 116 
prediction was selective of carboplatin response. As a result, biomarker defined subgroups 117 
of patients for whom platinum-based treatment may be selectively beneficial in the 118 
metastatic setting were deciphered.  119 
 5 
Patients and methods 120 
 121 
We analysed genome-wide allele specific copy number profiles from 135 TNT trial patients 122 
(NCT00532727)1 using Illumina HumanOmniExpress 24 SNP-arrays. The cohort included 131 123 
(97%) TNBC cases and 4 ER+ BRCA1/2 mutation carriers. Cases were categorised as: (i) 124 
germline or somatic BRCA1/2 mutation carriers without BRCA1 promoter methylation 125 
(n=20); (ii) BRCA1 methylated cases without BRCA1/2 mutations (n=19); (iii) BRCA1/2 wild-126 
type cases (n=75). Germline and somatic BRCA1/2 mutated cases were grouped together, as 127 
no statistically significant different chromosomal instability patterns were observed. 128 
Samples with ambiguous BRCA1/2 deficiency status (n=21) were excluded when the 129 
associations of CIN-measurements with BRCA1/2 mutation and BRCA1 methylation status 130 
were examined. 131 
 132 
The majority of the analysed BRCA1/2 mutated and BRCA1 promoter methylated cases were 133 
associated with LOH 19/20 (95%) of the BRCA1/2 mutated cases, 17/19 (89.5%) of the 134 
BRCA1 methylated cases. Three cases without LOH associated had moderate to low tumour 135 
purity (60%, 49% and 27%), however Myriad scores >42, thus indicating HR deficiency. Two 136 
cases with BRCA1 methylation without LOH exhibited only a moderate BRCA1 methylation 137 
level, yet above the 10% threshold1. 138 
 139 
The clinical baseline characteristics of the whole TNT trial (n=376) was comparable to the 140 
subset of patients with primary tumours (n=196), and the study cohort (n=135) (Figure 1, 141 
supplementary Table S1, available at Annals of Oncology online (for details see 142 
supplementary materials)).  143 
 144 
The copy number aberrations (CNAs) identified were used to derive the assessed 145 
quantitative measurements of CIN. Allelic imbalanced CNA (AiCNA), allelic balanced CNA 146 
(AbCNA), copy number neutral loss of heterozygosity (CnLOH) and number of telomeric 147 
allelic imbalances (NtAI) were calculated as previously described9. Percentage of genome 148 
altered (PGA) and Shannon diversity index16 (SI) were quantified based on the copy number 149 
(CN) profiles. Based on the observed unimodal distributions of the continuous CIN-150 
measurements, equally-sized tertiles (low, intermediate, high) were established. The 151 
BRCA1-like classifier17 was used to identify tumours with similar CN profiles to BRCA1 152 
mutation carriers. We composed a novel score termed high-level amplifications (HLAMP), 153 
which was defined based on the presence of at least 1 of the top 5% of recurrently amplified 154 
genomic regions (cytobands) in this cohort. These cytobands were located on 1q, 8q and 155 
10p chromosomal arms (including 1q21.1-24.1, 1q42.2-44, 8q11.21-24.3 and 10p15.3-14). 156 
The cohort was divided into three HLAMP groups: (i) samples lacking these amplifications 157 
were referred to as quiet; (ii) those with <50% amplified cytobands as low; (iii) >=50% 158 
amplified cytobands as high HLAMP, which was chosen based on the observed distribution 159 
of the HLAMP score. Cut-off points for all continuous CIN-measurements and the HLAMP 160 
score were determined blinded to the patient outcome. The Myriad HRD score was used to 161 
divide the cohort into HR deficient and HR proficient subgroups, as defined in the previous 162 
report on the TNT trial1.  163 
 164 
Illumina TruSight Cancer v2 targeted sequencing panel18 was used to identify pathogenic 165 
germline variants of 97 genes associated with predisposition to cancer.  166 
 6 
 167 
The association of CIN-measurements with ORR and PFS was assessed using logistic 168 
regression and restricted mean survival analysis, respectively. Detailed procedures are 169 
provided in the supplementary material, available at Annals of Oncology online. In the 170 
reporting process the REMARK guidelines were followed where applicable (supplementary 171 




Association between CIN features, BRCA1/2 mutation and BRCA1 promoter methylation 175 
 176 
Of 376 patients randomised in the TNT trial, genome profiles of primary tumours from 135 177 
patients were suitable for chromosomal instability assessment (see CONSORT diagram in 178 
Figure 1). Many of these tumours displayed highly aberrant genomes (Figure 2A), 179 
comparable to those in previously published series of TNBCs, such as the Guy’s Hospital 180 
King’s College London9 and METABRIC19 cohorts, when considering only those patients who, 181 
as in the TNT trial, developed metastases (supplementary material, supplementary Figure 182 
S1, available at Annals of Oncology online). As the majority of the samples were TNBCs, 183 
characteristic CNAs including gains on 1q, 3q, 8q, 10p or 12p and losses on 4q, 5q or 8p 184 
chromosomal arms were seen20 (Figure 2A). 185 
 186 
We first established nine different CIN-measurements to capture the consequences of 187 
diverse defects in DDR mechanisms that could lead to excessive genomic instability in TNBCs 188 
(Figure 2B). These included our three previously published “scores of chromosomal 189 
instability scarring” (SCINS) measures, namely AiCNA, AbCNA and CnLOH9. We also 190 
quantified the percentage of genome altered (PGA) measure21, a general proxy for the total 191 
amount of CNA across the whole genome; NtAI6, that was shown to be indicative of DDR 192 
deficiency and platinum sensitivity in TNBC patients; and the aCGH-based BRCA1-like 193 
classifier (BRCA1-like)5, that was shown to predict benefit from high-dose platinum-based 194 
chemotherapy. To measure the heterogeneity of the aberrant CN states, we introduced the 195 
Shannon diversity index (SI)16. In addition, a novel score termed HLAMP was derived from 196 
the observed amplifications in the CN profiles within the TNT cohort. The distribution of the 197 
novel HLAMP score was confirmed in the SCAN-B3, a TNBC cohort, and the TNBC subset of 198 
the METABRIC19 dataset. For both independent studies, tumours were selected when 199 
patients who, as necessary for TNT trial eligibility, developed relapse or distant metastasis 200 
(supplementary material, supplementary Figure S2). To complete this compendium of CIN-201 
measurements, the Myriad HRD score, as reported in the TNT study1, was also included.  202 
 203 
Then, we ensured that the characteristics of the CIN-measurements of the ER+ BRCA1/2 204 
mutation carriers were consistent with the rest of the TNT study cohort (supplementary 205 
Figure S3, supplementary Table S3).  206 
 207 
Next, the extent of each of the nine CIN-measurements were compared between those TNT 208 
trial cases with pathogenic germline or somatic BRCA1/2 mutations, BRCA1 methylated and 209 
BRCA1/2 wild-type cancers. Continuous CIN-measurements, such as NtAI, AiCNA, AbCNA, 210 
CnLOH and PGA scores displayed similar distributions across all three subgroups (Figure 2C). 211 
In alignment with our previous study1, HR deficient cases were clearly associated with the 212 
presence of BRCA1/2 mutation and BRCA1 promoter methylation (Kruskal-Wallis rank sum 213 
test P=1.61e-17) (Figure 2C, supplementary Table S4, available at Annals of Oncology 214 
online). The majority of tumours (76%, 103/135) were classified as BRCA1–like17, including 215 
80% (16/20) of BRCA1/2 mutated and 73% (14/19) of BRCA1 methylated cases. In 55% 216 
(11/20) of germline and somatic BRCA1/2 mutation carriers, tumours were categorised as 217 
quiet HLAMP, whilst 35% (7/20) and 10% (2/20) were grouped into the low and high HLAMP 218 
groups respectively. Conversely, tumours with BRCA1 promoter methylation were most 219 
 8 
prominent in the low HLAMP subgroup (68%, 13/19), and were present at a significantly 220 
lesser extent in the quiet (3/19) and high (4/19) HLAMP categories (Fisher’s exact 221 
Padj=0.029, Figure 2C, supplementary Table S4, available at Annals of Oncology online).  222 
 223 
Association of germline variants in additional DDR related cancer predisposition genes 224 
with CIN features 225 
 226 
Pathogenic germline variants in DDR genes18 increase the risk of developing cancer and 227 
were identified in peripheral blood leukocyte DNA in 8/135 patients, not including BRCA1/2 228 
(supplementary Table S5, available at Annals of Oncology online). The majority (62.5%, 5/8) 229 
of these cases were part of the low HLAMP group, and were completely absent in the high 230 
group (Figure 2B). Moreover, tumours of patients with germline variants in DDR genes had 231 
high Shannon diversity score (62.5%, 5/8) and were more often classified as being BRCA1-232 
like (75%, 6/8) or HR deficient (62.5%, 5/8), but small numbers limit conclusive 233 
interpretation of these data (Figure 2B). 234 
 235 
CIN measures as biomarkers for chemotherapy response 236 
 237 
Next we asked whether any of the nine established CIN-measurements carried prognostic or 238 
predictive value within the TNT trial.  239 
 240 
Subgroup analyses indicated that patients with tumours of the intermediate NtAI subgroup 241 
had a significantly better response to carboplatin than docetaxel (ORR: 13/24 (54%) vs 4/20 242 
(20%) PNtAI,intermediate = 0.03) (Figure 3A, supplementary Table S6), and patients with tumours 243 
of the intermediate AiCNA subgroup also appeared to have better response to carboplatin 244 
than docetaxel (ORR: 13/21 (62%) vs 8/24 (33%) PAiCNA,intermediate = 0.076) (Figure 3B, 245 
supplementary Table S6). For both, a trend for interaction between treatment group and 246 
AiCNA (Pinteraction/AiCNA = 0.060) and NtAI (Pinteraction/NtAI = 0.083) was observed, which 247 
remained evident after adjustment for clinical covariates (for details see supplementary 248 
material), including BRCA1/2 mutation status (Padj.interaction/AiCNA = 0.024, Padj.interaction/NtAI = 249 
0.016). Whilst no significant interactions were found between treatment and any of the 250 
other tested CIN-measurements, a numerically higher ORR was observed in the carboplatin 251 
arm in the intermediate CnLOH group (ORR: 12/25 (48%) (C) vs 3/20 (15%) (D), 252 
PCnLOH,medium=0.027) and in the quiet HLAMP group (ORR: 14/25 (56%) (C) vs 7/24 (29%) (D), 253 
PHLAMP,quiet=0.085) (Figure 3C, supplementary Table S6).  254 
 255 
Patients with carcinomas in the quiet HLAMP group had an improved PFS with carboplatin 256 
versus docetaxel; and this association remained significant following adjustment for clinical 257 
variables including BRCA1/2 mutation (restricted mean PFS 6.1 months (C) versus 4.1 258 
months (D), Pinteraction/HLAMP=0.047 and Padj.interaction/HLAMP=0.033; Figure 3D). Trends for 259 
interaction of treatment with AiCNA (Pinteraction/AiCNA=0.027) and with PGA 260 
(Pinteraction/PGA=0.053) were observed, showing the shortest PFS in cases with the highest PGA 261 
scores and in the high AiCNA subgroup in the carboplatin arm. However, these interactions 262 
were lost after adjustment for clinical covariates (Padj.interaction/AiCNA=0.125, 263 
Padj.interaction/PGA=0.176) (Figures 3E, 3F). Sixty-seven of 135 primary tumours showed low to 264 
intermediate CIN burden based on AiCNA and PGA scores. Within this subgroup carboplatin 265 
 9 
responders were more prevalent (64%, 18/28) in comparison to docetaxel responders (39%, 266 
9/23) (supplementary Figure S4).  267 
 268 
Lastly, we excluded the 4 ER+ BRCA1/2 mutation carriers from the outcome analyses, which 269 
showed that the results and derived conclusions remained essentially unaffected, 270 
supporting the plausibility of the inclusion the ER+ cases (supplementary Table S7). 271 




The FDA approved olaparib and talazoparib in 2018 for patients with confirmed germline 275 
BRCA1/2 mutation22, 23, including those with TNBC, providing one of the first targeted 276 
therapy options for a subset of TNBC patients. However, the majority of TNBC patients lack 277 
germline BRCA1/2 mutations, and are treated with either standard-of-care chemotherapy or 278 
in some circumstances with immunotherapy24. By exploring the highly aberrant genomes of 279 
TNBC, several “genomic scars” caused by disruptions of DDR mechanisms, have been 280 
developed and carry some predictive value for treatment responses to chemotherapy in the 281 
neoadjuvant setting. However, the specificity of the prediction of platinum response, which 282 
is distinct from more generic chemotherapy response, is unclear in this setting2, 5-7, 9, 25. 283 
 284 
The randomised controlled TNT trial provides the opportunity to dissect genomic features 285 
and differentiate response to mechanistically highly distinct carboplatin and docetaxel 286 
treatments in metastatic or locally advanced TNBC. Indeed, we identified intermediate 287 
levels of allelic imbalanced CNAs, as measured by AiCNA, that focuses on genomic segments 288 
larger than 8 Mbp9, and telomeric NtAI6 as being differentially associated with improved 289 
ORR in the carboplatin arm. Moreover, we noticed that in the TBCRC009 trial15, in which 290 
metastatic TNBC patients were treated with platinum monotherapy, the highest levels of 291 
tumour response were observed in cases with medium levels of the “genomic scar” assays 292 
developed by Myriad that measure large LOH events (HRD-LOH)7 and large-scale state 293 
transition events (HRD-LST)8, both of which have been associated with HR deficiency. Our 294 
analyses of the TNT trial allow the testing of the specific interaction of these measures with 295 
platinum, as opposed to mechanistically distinct docetaxel, chemotherapy, and suggest that 296 
an intermediate CIN phenotype may represent a selective biomarker for platinum-based 297 
treatment response (as opposed to taxanes) in TNBC. Furthermore, AiCNA, and PGA, as well 298 
as the HLAMP scores, were associated with differential carboplatin effect as defined by PFS. 299 
As HLAMP was developed by analysis within this dataset this result must be regarded as 300 
hypothesis-generating. 301 
 302 
Response to carboplatin, a DNA cross-linking agent, is related to the cell’s failure to 303 
successfully repair and survive the induced DNA damage. This prompted us to examine the 304 
utility of CIN-measurements as predictors of carboplatin response, as they can provide 305 
genomic evidence of disruption of DDR mechanisms reflected in acquired genome damage. 306 
In contrast, the cytotoxic effect of docetaxel is mediated by the stabilisation of normally 307 
dynamic microtubule assembly during mitotic cell division leading to cell death. In 308 
agreement with our observations it was, therefore, not anticipated that “genomic scars” of 309 
DNA repair deficiency should be selectively associated with docetaxel response. 310 
 311 
Limitations of this study include the low resolution of the SNP-array platform that was used 312 
and the potential confounding factor of selecting a certain biological subset of TNBC. 313 
Although the ideal tissue resource for a predictive biomarker study of patients with 314 
metastatic/advanced breast carcinoma would be a set of metastatic biopsies, these were 315 
not regularly collected at the time of conduct of the TNT trial. There may, therefore, have 316 
been selection of DDR related resistance by DNA damage inducing adjuvant therapy 317 
between primary diagnosis and trial entry with advanced disease, hence the biology of 318 
these recurrent tumours may not be adequately represented by archival primary invasive 319 
 11 
cancer tissues. Nevertheless, the copy number landscape of these archival primary tumours 320 
in the TNT trial did display distinctive CNAs, including known amplifications and losses, that 321 
are characteristic of TNBCs occurring in patients who develop metastatic disease. 322 
 323 
In summary, the somatic genome profiles of these series of TNT trial cases provide an 324 
opportunity to explore the molecular features of TNBC and their association with treatment 325 
response of metastases to two single agent chemotherapies with highly distinct 326 
mechanisms of action. The finding that intermediate levels of allelic imbalanced CNAs 327 
determined by AiCNA and NtAI are selectively predictive of carboplatin responses offers a 328 
potential approach to find specific associations to platinum response. Moreover, we found a 329 
signal that requires validation in other TNBC cohorts that patients with tumours displaying 330 
intermediate CIN scores, as well as those with tumours lacking high level amplifications 331 
(HLAMP), have differential prediction of response. If our findings are substantiated they may 332 
potentially facilitate the prediction of a wider subgroup of TNBC patients who might be 333 
selected for platinum-based chemotherapy and support the potential integration of 334 
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Patients with primary tumour sample (n = 196)
180 patients excluded:
• No tumour DNA was available for SNP-array analysis
53 patients excluded:
• ASCAT Goodness of fit < 80% (n = 26)
• ASCAT Aberrant Cell Fraction was estimated 100% (n = 27)
Patients with evaluable copy 
number profiles (n = 143)
8 patients excluded:
• Not centrally confirmed TNBC and BRCA1/2 wild-type (n = 5)
• Not centrally confirmed TNBC and BRCA1/2 status unknown (n = 2)
• HER2 status unknown and BRCA1/2 wild-type (n = 1)
Patients with evaluable TNBC 
and/or BRCA1/2 mutated tumours (n = 135)
• BRCA1/2 proficient (n = 75)
• BRCA1/2 mutation (n = 20)
• BRCA1 promoter methylation (n = 19)
Figure 1.
BRCA1/2 status ambiguous (n = 21):
• Unknown germline BRCA1/2 status, somatic BRCA1/2 wild-type (n = 12)
• Germline BRCA1/2 wild-type, failed assessment of somatic BRCA1/2 status (n = 3)
• Germline BRCA1 mutation, BRCA1 mutation not detected in tumour (n = 1)
• BRCA1 methylation status not assessed (n = 4)
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22 13(9) 8(5) 2(6) 0(2)High
20 8(12) 4(4) 3(1) 2(1)Low
25 17(8) 13(4) 6(7) 4(2)Quiet
N at risk (events)























17 12(5) 7(5) 1(7) 0(0)High
27 18(9) 7(11) 2(5) 0(2)Low
24 17(7) 4(13) 0(4) 0(0)Quiet
N at risk (events)





























21 9(12) 3(6) 2(1) 1(2)High
21 14(7) 11(3) 5(6) 2(3)Intermediate
25 15(10) 11(4) 4(7) 3(1)Low
N at risk (events)























24 17(7) 7(10) 1(7) 0(0)High
24 18(6) 7(11) 2(5) 0(2)Intermediate
20 12(8) 4(8) 0(4) 0(0)Low
N at risk (events)





























22 10(12) 5(5) 2(3) 1(1)
22 14(8) 8(6) 5(3) 2(3)
23 14(9) 12(2) 4(8) 3(1)
N at risk (events)























23 17(6) 7(10) 1(7) 0(0)
23 16(7) 8(8) 2(6) 0(2)
22 14(8) 3(11) 0(3) 0(0)
N at risk (events)
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TNT cohort - unknown BRCA1/2 status at trial entry (n=124)













































































































































































































Shannon index0.32 0.24 0.1 0.34 0.15 0.57 0.52 0.46 1
0.56 0.31 −0.02 0.42 −0.06 0.6 0.52 1
0.34 0 −0.17 0.08 −0.38 0.53 1
0.51 0.23 −0.02 0.22 −0.17 1
−0.12 0.32 0.16 0.35 1
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Shannon diversity group (n=135)
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Supplementary Figure Legends 1 
 2 
Supplementary Figure S1 3 
The frequency of copy number gains and losses across the whole genome of primary 4 
tissue samples of the (A) patients without known germline BRCA1/2 mutation status 5 
at trial entry in the TNT cohort (n=124), (B) KCL subset (n=47), (B) METABRIC subset 6 
(n=50) with reported relapse. The complete KCL and METABRIC breast cancer 7 
cohorts were manually curated to include only triple negative samples that were 8 
reported to have been developed local or metastatic recurrences. 9 
 10 
Supplementary Figure S2 11 
The distribution of the amplified HLAMP regions across the (A) TNT cohort (n=135), 12 
(B) METABRIC TNBC subset with reported relapse (n=50), (C) SCAN-B metastatic 13 
subset (n=56). Each column represents a sample. The presence of an amplification is 14 
shown in red. The amplification frequencies of the HLAMP cytobands are displayed 15 
as bar plots next to each corresponding heatmap. The HLAMP subgroups are 16 
indicated on top (quiet = blue, low = yellow, high =red).  17 
 18 
Supplementary Figure S3 19 
Comparison of the distribution of the CIN-measurements (A) AiCNA, (B) AbCNA, (C) 20 
CnLOH, (D) NtAI and (E) PGA among the BRCA1/2 deficiency subgroups (WT = wild-21 
type, MET = BRCA1 methylated, MUT = BRCA1/2 mutated) are displayed. The ER+ 22 
cases are coloured in red. 23 
 24 
Supplementary Figure S4 25 
Schematic display of AiCNA, PGA and HLAMP status that provided evidence of 26 
interaction with treatment response in the carboplatin and docetaxel arms for each 27 
case. PGA and AiCNA are presented on log2 scale, and vertical and horizontal lines 28 
show the boundaries between the subgroups at the tertiles of the CIN-29 
measurements. HLAMP status is colour coded as red = high, yellow = low and blue = 30 
quiet HLAMP group. Solid circle = reported objective response, cross = no objective 31 
response. 32 
 33 
Supplementary Figure S5 34 
Correlation matrix showing the Spearman correlation coefficients among the CIN-35 
measurements for the primary tumour samples (n=135). BRCA1-like values represent 36 
the probability score from the BRCA1-like classification. Colour coding indicates the 37 
strength of the correlation. Asterisks show if the p-value associated with the 38 
Spearman correlation was P < 0.05. 39 
  40 
Supplementary Figure S6 41 
Comparison of the distribution of the CIN-measurements among the homologous 42 
recombination deficiency (HRD) subgroups, (A) AiCNA, (B) AbCNA, (C) CnLOH, (D) 43 
NtAI, (E) PGA, (F) SI, (G) HLAMP. P-values of Wilcoxon tests are shown. The p-values 44 
were corrected for multiple comparisons by the Benjamini-Hochberg method. 45 
 46 
Supplementary Figure S7 47 
Comparison of the distribution of the CIN-measurements among the Shannon index 48 
(SI) subgroups, (A) AiCNA, (B) AbCNA, (C) CnLOH, (D) NtAI, (E) PGA, (F) HLAMP, (G) 49 
HRD scores. P-values of Kruskal-Wallis rank sum tests are shown. The p-values were 50 
corrected for multiple comparisons by the Benjamini-Hochberg method. 51 
 52 
Supplementary Figure S8 53 
Comparison of the distribution of the CIN-measurements among the BRCA1-like 54 
subgroups, (A) AiCNA, (B) AbCNA, (C) CnLOH, (D) NtAI, (E) PGA, (F) SI, (G) HLAMP, (H) 55 
HRD scores. P-values of Wilcoxon tests are shown. The p-values were corrected for 56 
multiple comparisons by the Benjamini-Hochberg method. 57 
 58 
Supplementary Figure S9 59 
Comparison of the distribution of the CIN-measurements among the HLAMP groups, 60 
(A) AiCNA, (B) AbCNA, (C) CnLOH, (D) NtAI, (E) PGA, (F) SI, (G) HRD scores. P-values 61 
of Kruskal-Wallis rank sum test are shown. The p-values were corrected for multiple 62 
comparisons by the Benjamini-Hochberg method. 63 
 64 
Supplementary Figure S10 65 
Scatterplots showing the associations between with tumour purity (by ASCAT 66 
algorithm) and (A) AiCNA, (B) AbCNA, (C) CnLOH, (D) NtAI, (E) PGA as continuous 67 
variables, and (F) the percentage of BRCA1 promoter methylation in the TNT study 68 
cohort (n=135). Spearman correlation coefficient (rho) and associated p-values (P) 69 
are shown in the top left corner. Fitted line of linear regression is indicated in red. 70 
 71 
Supplementary Figure S11 72 
Boxplots showing the associations between with tumour purity (by ASCAT algorithm) 73 
and (A) HLAMP, (B) Shannon diversity groups as categorical variables, (C) BRCA1-like 74 
status, (D) HRD status, and (E) the BRCA1 promoter methylation status in the TNT 75 
study cohort (n=135). In the cases of HRD and BRCA1 methylation status data is 76 
available for n=131 patients. P-values of Kruskal-Wallis rank sum tests are shown in 77 
the top left corner. The p-values were adjusted for multiple comparisons with the 78 
Benjamini-Hochberg method. 79 
 80 
Supplementary Figure S12 81 
Comparison of the distribution of PGA between the reduced TNT cohort (n=124) 82 
(including patients without known BRCA1/2 mutation status at trial entry) and the 83 
KCL and METABRIC triple negative metastatic subsets on (A) boxplots and (B) density 84 
plots. P-value of Kruskal-Wallis rank sum test is shown.  85 
 86 
 87 
PGA = percentage genome altered, AbCNA = allelic balanced CNA, AiCNA = allelic 88 
imbalanced CNA, NtAI = number of telomeric allelic imbalances, HRD score = 89 
homologous recombination deficiency score, CnLOH = copy number neutral loss of 90 
heterozygosity, HLAMP = high-level amplifications, BRCA1-like = probability score for 91 
BRCA1-like classification, SI = Shannon index, KCL = King’s College London, MB = 92 
METABRIC. 93 
Supplementary Table S1. Clinical baseline characteristics of (A) TNT trial cohort (n=376), (B) patients with available DNA (n=196) and (C) TNT 






TNT trial cohort (n=376) 
 Carboplatin Docetaxel Total 
 No. % No. % No. % 
Age group [years]       
<35 14 7.4 21 11.2 35 9.3 
35-40 47 25 39 20.7 86 22.9 
40-45 63 33.5 67 35.6 130 34.6 
45-50 64 34 61 32.4 125 33.2 
Ethnic Origin       
Any other ethnic group 1 0.5 2 1.1 3 0.8 
Asian or Asian British: 
Bangladesh 2 1.1 0 0 2 0.5 
Asian or Asian British: 
Indian 3 1.6 0 0 3 0.8 
Asian or Asian British: 
Pakistani 1 0.5 2 1.1 3 0.8 
Black or Black British: 
African 6 3.2 3 1.6 9 2.4 
Black or Black British: 
Caribbean 4 2.1 6 3.2 10 2.7 
Mixed: White and Black 
Caribbean 0 0 1 0.5 1 0.3 
Not stated 5 2.7 2 1.1 7 1.9 
Other Asian Background 2 1.1 1 0.5 3 0.8 
Other Black Background 3 1.6 1 0.5 4 1.1 
Other White background 4 2.1 6 3.2 10 2.7 
White: British 154 81.9 161 85.6 315 83.8 
White: Irish 1 0.5 2 1.1 3 0.8 
Missing 2 1.1 1 0.5 3 0.8 
Carcinoma Type       
Recurrent locally advanced 20 10.6 19 10.1 39 10.4 
Metastatic 168 89.4 169 89.9 337 89.6 
ECOG performance status       
0-1 174 92.6 176 93.6 350 93.1 
2 14 7.4 12 6.4 26 6.9 
Previous taxane 
chemotherapy 
      
Yes 65 34.6 61 32.4 126 33.5 
No 123 65.4 127 67.6 250 66.5 
Liver or lung metastases       
Yes 98 52.1 100 53.2 198 52.7 
No 90 47.9 88 46.8 178 47.3 
Time since diagnosis to 
initial relapse [years] 
      
0-1 from 31 16.5 41 21.8 72 19.1 
1-3 years 100 53.2 89 47.3 189 50.3 
3-5 years 41 21.8 33 17.6 74 19.7 
>5 years 16 8.5 25 13.3 41 10.9 
Visceral disease present at 
baseline 
      
No 52 27.7 52 27.7 104 27.7 
Yes 136 72.3 136 72.3 272 72.3 
Germline BRCA1/2 
mutational status* 
      
No mutation 128 68.1 145 77.1 273 72.6 
BRCA1 mut 16 8.5 15 8 31 8.2 
BRCA2 mut 9 4.8 3 1.6 12 3.2 
Unknown 35 18.6 25 13.3 60 16 
Tumour BRCA1/2 
mutational status* 
      
Negative 90 47.9 90 47.9 180 47.9 
Positive 18 9.6 14 7.4 32 8.5 
Uncertain 1 0.5 6 3.2 7 1.9 
Untested 79 42 78 41.5 157 41.8 
BRCA1 methylation*       
Non-methylated 93 49.5 86 45.7 179 47.6 
Methylated 14 7.4 19 10.1 33 8.8 
Unknown 81 43.1 83 44.1 164 43.6 
Surgery of primary disease       
Yes 166 88.3 163 86.7 329 87.5 
No 18 9.6 22 11.7 40 10.6 
Missing 4 2.1 3 1.6 7 1.9 
Axillary lymph node 
surgery performed 
      
Yes 166 88.3 158 84 324 86.2 
No 20 10.6 24 12.8 44 11.7 
Missing 2 1.1 6 3.2 8 2.1 
Number of lymph nodes 
involved 
      
N- 96 51.1 95 50.5 191 50.8 
1-3N+ 53 28.2 51 27.1 104 27.7 
>=4N+ 39 20.7 42 22.3 81 21.5 
Side of primary tumour       
Left 108 57.4 111 59 219 58.2 
Right 78 41.5 74 39.4 152 40.4 
Missing 2 1.1 3 1.6 5 1.3 
Vascular invasion       
Yes 80 42.6 69 36.7 149 39.6 
No 76 40.4 83 44.1 159 42.3 
Not reported 28 14.9 30 16 58 15.4 
Missing 4 2.1 6 3.2 10 2.7 
Tumour grade       
1 0 0 2 1.1 2 0.5 
2 28 14.9 29 15.4 57 15.2 
3 151 80.3 150 79.8 301 80.1 
Not known 6 3.2 4 2.1 10 2.7 
Missing 3 1.6 3 1.6 6 1.6 
Pathological invasive 
tumour size 
      
<2cm 42 22.3 40 21.3 82 21.8 
2-5cm 100 53.2 108 57.4 208 55.3 
>5cm 26 13.8 17 9 43 11.4 
Missing 20 10.6 23 12.2 43 11.4 
Histological Type       
Infiltrating ductal 158 84 161 85.6 319 84.8 
Infiltrating lobular 4 2.1 5 2.7 9 2.4 
Mixed ductal & lobular 3 1.6 3 1.6 6 1.6 
Other 18 9.6 14 7.4 32 8.5 
Missing 5 2.7 5 2.7 10 2.7 
Anthracycline 
chemotherapy for 
      
metastatic/locally 
advanced disease 
Yes 16 8.5 20 10.6 36 9.6 
No 172 91.5 166 88.3 338 89.9 






TNT cohort – DNA available (n=196) 
 Carboplatin Docetaxel Total 
 No. % No. % No. % 
Age group [years]       
<35 8 8.3 13 13 21 10.7 
35-40 25 26 22 22 47 24 
40-45 34 35.4 38 38 72 36.7 
45-50 29 30.2 27 27 56 28.6 
Ethnic Origin       
Any other ethnic group 1 1 0 0 1 0.5 
Asian or Asian British: 
Bangladesh 2 2.1 0 0 2 1 
Asian or Asian British: 
Indian 2 2.1 0 0 2 1 
Asian or Asian British: 
Pakistani 0 0 1 1 1 0.5 
Black or Black British: 
African 3 3.1 2 2 5 2.6 
Black or Black British: 
Caribbean 3 3.1 5 5 8 4.1 
Mixed: White and Black 
Caribbean 0 0 1 1 1 0.5 
Not stated 2 2.1 1 1 3 1.5 
Other Asian Background 1 1 0 0 1 0.5 
Other Black Background 1 1 0 0 1 0.5 
Other White background 2 2.1 2 2 4 2 
White: British 79 82.3 86 86 165 84.2 
White: Irish 0 0 2 2 2 1 
Missing 0 0 0 0 0 0 
Carcinoma Type       
Recurrent locally advanced 7 7.3 11 11 18 9.2 
Metastatic 89 92.7 89 89 178 90.8 
ECOG performance status       
0-1 88 91.7 92 92 180 91.8 
2 8 8.3 8 8 16 8.2 
Previous taxane 
chemotherapy       
Yes 39 40.6 37 37 76 38.8 
No 57 59.4 63 63 120 61.2 
Liver or lung metastases       
Yes 58 60.4 54 54 112 57.1 
No 38 39.6 46 46 84 42.9 
Time since diagnosis to 
initial relapse [years]       
0-1 from 8 8.3 19 19 27 13.8 
1-3 years 60 62.5 51 51 111 56.6 
3-5 years 22 22.9 19 19 41 20.9 
>5 years 6 6.3 11 11 17 8.7 
Visceral disease present at 
baseline       
No 21 21.9 26 26 47 24 
Yes 75 78.1 74 74 149 76 
Germline BRCA1/2 
mutational status*       
No mutation 73 76 82 82 155 79.1 
BRCA1 mut 10 10.4 8 8 18 9.2 
BRCA2 mut 2 2.1 1 1 3 1.5 
Unknown 11 11.5 9 9 20 10.2 
Tumour BRCA1/2 
mutational status*       
Negative 79 82.3 81 81 160 81.6 
Positive 16 16.7 14 14 30 15.3 
Uncertain 1 1 5 5 6 3.1 
Untested 0 0 0 0 0 0 
BRCA1 methylation*       
Non-methylated 83 86.5 76 76 159 81.1 
Methylated 11 11.5 19 19 30 15.3 
Unknown 2 2.1 5 5 7 3.6 
Surgery of primary disease       
Yes 95 99 98 98 193 98.5 
No 0 0 2 2 2 1 
Missing 1 1 0 0 1 0.5 
Axillary lymph node 
surgery performed       
Yes 96 100 95 95 191 97.4 
No 0 0 5 5 5 2.6 
Missing 0 0 0 0 0 0 
Number of lymph nodes 
involved       
N- 46 47.9 40 40 86 43.9 
1-3N+ 27 28.1 29 29 56 28.6 
>=4N+ 23 24 31 31 54 27.6 
Side of primary tumour       
Left 54 56.3 65 65 119 60.7 
Right 42 43.8 35 35 77 39.3 
Missing 0 0 0 0 0 0 
Vascular invasion       
Yes 52 54.2 48 48 100 51 
No 40 41.7 42 42 82 41.8 
Not reported 4 4.2 10 10 14 7.1 
Missing 0 0 0 0 0 0 
Tumour grade       
1 0 0 1 1 1 0.5 
2 10 10.4 11 11 21 10.7 
3 86 89.6 87 87 173 88.3 
Not known 0 0 1 1 1 0.5 
Missing 0 0 0 0 0 0 
Pathological invasive 
tumour size       
<2cm 18 18.8 18 18 36 18.4 
2-5cm 62 64.6 70 70 132 67.3 
>5cm 15 15.6 8 8 23 11.7 
Missing 1 1 4 4 5 2.6 
Histological Type       
Infiltrating ductal 84 87.5 89 89 173 88.3 
Infiltrating lobular 2 2.1 2 2 4 2 
Mixed ductal & lobular 1 1 1 1 2 1 
Other 9 9.4 8 8 17 8.7 




advanced disease       
Yes 4 4.2 7 7 11 5.6 
No 92 95.8 92 92 184 93.9 






TNT study cohort (n=135) 
 Carboplatin Docetaxel Total 
 No. % No. % No. % 
Age group [years]       
<35 7 10.4 8 11.8 15 11.1 
35-40 20 29.9 15 22.1 35 25.9 
40-45 23 34.3 26 38.2 49 36.3 
45-50 17 25.4 19 27.9 36 26.7 
Ethnic Origin       
Any other ethnic group 
1 1.5 0 0 1 0.7 
Asian or Asian British: 
Bangladesh 1 1.5 0 0 1 0.7 
Asian or Asian British: 
Indian 2 3 0 0 2 1.5 
Asian or Asian British: 
Pakistani 0 0 0 0 0 0 
Black or Black British: 
African 1 1.5 2 2.9 3 2.2 
Black or Black British: 
Caribbean 2 3 5 7.4 7 5.2 
Mixed: White and Black 
Caribbean 0 0 0 0 0 0 
Not stated 2 3 1 1.5 3 2.2 
Other Asian Background 1 1.5 0 0 1 0.7 
Other Black Background 1 1.5 0 0 1 0.7 
Other White background 2 3 2 2.9 4 3 
White: British 54 80.6 58 85.3 112 83 
White: Irish 0 0 0 0 0 0 
Missing 0 0 0 0 0 0 
Carcinoma Type       
Recurrent locally advanced 4 6 7 10.3 11 8.1 
Metastatic 63 94 61 89.7 124 91.9 
ECOG performance status       
0-1 61 91 61 89.7 122 90.4 
2 6 9 7 10.3 13 9.6 
Previous taxane 
chemotherapy       
Yes 26 38.8 25 36.8 51 37.8 
No 41 61.2 43 63.2 84 62.2 
Liver or lung metastases       
Yes 39 58.2 37 54.4 76 56.3 
No 28 41.8 31 45.6 59 43.7 
Time since diagnosis to 
initial relapse [years]       
0-1 from 6 9 13 19.1 19 14.1 
1-3 years 40 59.7 35 51.5 75 55.6 
3-5 years 16 23.9 14 20.6 30 22.2 
>5 years 5 7.5 6 8.8 11 8.1 
Visceral disease present at 
baseline       
No 17 25.4 18 26.5 35 25.9 
Yes 50 74.6 50 73.5 100 74.1 
Germline BRCA1/2 
mutational status*       
No mutation 50 74.6 55 80.9 105 77.8 
BRCA1 mut 9 13.4 5 7.4 14 10.4 
BRCA2 mut 1 1.5 1 1.5 2 1.5 
Unknown 7 10.4 7 10.3 14 10.4 
Tumour BRCA1/2 
mutational status*       
Negative 53 79.1 57 83.8 110 81.5 
Positive 13 19.4 9 13.2 22 16.3 
Uncertain 1 1.5 2 2.9 3 2.2 
Untested 0 0 0 0 0 0 
BRCA1 methylation*       
Non-methylated 58 86.6 51 75 109 80.7 
Methylated 8 11.9 13 19.1 21 15.6 
Unknown 1 1.5 4 5.9 5 3.7 
Surgery of primary disease       
Yes 67 100 67 98.5 134 99.3 
No 0 0 1 1.5 1 0.7 
Missing 0 0 0 0 0 0 
Axillary lymph node 
surgery performed       
Yes 67 100 65 95.6 132 97.8 
No 0 0 3 4.4 3 2.2 
Missing 0 0 0 0 0 0 
Number of lymph nodes 
involved       
N- 33 49.3 25 36.8 58 43 
1-3N+ 16 23.9 20 29.4 36 26.7 
>=4N+ 18 26.9 23 33.8 41 30.4 
Side of primary tumour       
Left 40 59.7 43 63.2 83 61.5 
Right 27 40.3 25 36.8 52 38.5 
Missing 0 0 0 0 0 0 
Vascular invasion       
Yes 35 52.2 33 48.5 68 50.4 
No 29 43.3 29 42.6 58 43 
Not reported 3 4.5 6 8.8 9 6.7 
Missing 0 0 0 0 0 0 
Tumour grade       
1 0 0 1 1.5 1 0.7 
2 9 13.4 6 8.8 15 11.1 
3 58 86.6 61 89.7 119 88.1 
Not known 0 0 0 0 0 0 
Missing 0 0 0 0 0 0 
Pathological invasive 
tumour size       
<2cm 12 17.9 11 16.2 23 17 
2-5cm 43 64.2 50 73.5 93 68.9 
>5cm 11 16.4 6 8.8 17 12.6 
Missing 1 1.5 1 1.5 2 1.5 
Histological Type       
Infiltrating ductal 57 85.1 59 86.8 116 85.9 
Infiltrating lobular 2 3 0 0 2 1.5 
Mixed ductal & lobular 0 0 1 1.5 1 0.7 
Other 8 11.9 8 11.8 16 11.9 




advanced disease       
Yes 2 3 5 7.4 7 5.2 
No 65 97 62 91.2 127 94.1 
Missing 0 0 1 1.5 1 0.7 
 
*When BRCA1/2 mutational status was determined, in order to completely separate the effect of BRCA1/2 mutation and BRCA1 promoter methylation, only samples with 
either mutation or methylation were included. Out of the 22 BRCA1/2 mutation carriers and 21 BRCA1 promoter methylated cases, 1 sample was excluded because of 
being both mutated and methylated, 1 BRCA1 methylated sample with unknown BRCA1/2 status and 1 BRCA1/2 mutated sample with unknown BRCA1 methylation status 
were excluded, resulting in 20 BRCA1/2 mutated and 19 BRCA1 promoter methylated cases.   
Supplementary Table S2. The REMARK checklist as published by McShane et al., British 






checklist item Description TNT manuscript 
Introduction   






Patients   
2 Describe the characteristics (eg disease stage or co-
morbidities) of study patients, including their source and 
inclusion and exclusion criteria 
ü In original TNT 
publication 
3 Describe treatments received and how chosen (eg 
randomized or rule-based). 





4 Describe the type of biological material used (incl. control 
samples) and methods for preservation. 





5 Specify the assay method used and provide (or reference) a 
detailed protocol, incl. specific reagents or kits used, quality 
control procedures, reproducibility assessment, quantitation 
methods, and scoring and reporting protocols. Specify 
whether and how assays were performed blinded to the study 
endpoint. 
ü In original TNT 
publication 
Study design   
6 State the method of case selection, including whether 
prospective or retrospective and whether stratification or 
matching (eg by stage of disease or age) was used. Specify 
the time period from which cases were taken, the end of the 
follow-up period, and the median-follow-up time. 
ü Materials and 
Methods 
7 Precisely define all clinical endpoints examined. ü Materials and 
Methods 
8 List all candidate variables initially examined or considered 
for inclusion in models. 
ü Materials and 
Methods 
9 Give rational for sample size; if the study was designed to 
detect a specified effect size, give the target power and effect 
size. 
ü Sample size was 







10 Specify all statistical methods, including details of any 
variable selection procedures and other model-building 
issues, how model assumptions were verified, and how 
missing data were handled. 
ü Materials and 
Methods 
11 Clarify how marker values were handled in the analyses; if 
relevant, describe methods used for cutpoint determination. 






Results   
Data   
12 Describe the flow of patients through the study, including 
the number of patients included in each stage of the analysis 
(a diagram may be helpful) and reasons for dropout. 
Specifically, both overall and for each subgroup extensively 




13 Report distributions of basic demographic characteristics (at 
least age and sex), standard (disease-specific) prognostic 







14 Show the relation of the marker to standard prognostic 
variables 
 
15 Present univariable analysis showing the relation between 
the marker and outcome, with the estimated effect (eg 
hazard ratio and survival probability). Preferably provide 
similar analyses for all other variables being analyzed. For 
the effect of a tumor marker on a time-to-event outcome, a 
Kaplan-Meier plot is recommended. 
 
16 For key multivariable analyses, report estimated effects (eg 
hazard ratio) with confidence intervals for the marker and, at 
least for the final model, all other variables in the model. 
 
17 Among reported results, provide estimated effects with 
confidence intervals from an analysis in which the marker 
and standard prognostic variables are included, regardless of 
their statistical significance. 
 
18 If done, report results of further investigations, such as 




Discussion   
19 Interpret the results in the context of the pre-specified 
hypotheses and other relevant studies; include a discussion 
of limitations of the study. 
ü Discussion 
20 Discuss implications for further research and clinical value. ü Discussion 
 




CIN measurements TNT72 TNT147 TNT227 TNT232 
Germline BRCA1 
mutation* 0 1 1 0 
Germline BRCA2 
mutation* 1 0 0 1 
Tumour 
BRCA1 mutation* 1 1 1 0 
Tumour 
BRCA2 mutation* 1 0 0 1 
BRCA1 methylation Non-methylated Non-methylated Non-methylated Non-methylated 
AiCNA** 1.04 (Low) 5.89 (Low) 15.8 (Medium) 9.21 (Low) 
AbCNA** 1 (Low) 3 (Low) 1 (Low) 0 (Low) 
CnLOH** 0.04 (Low) 7.72 (High) 3.4 (High) 0.25 (Low) 
NtAI** 7 (Low) 21 (Medium) 30 (High) 18 (Low) 
PGA** 11.85 (Low) 28.02 (Low) 43.87 (Low) 31.75 (Low) 
HLAMP Quiet Quiet Low Low 
Shannon diversity Medium Low Low Medium 
BRCA1-like Not BRCA1-like BRCA1-like BRCA1-like Not BRCA1-like 
HRD HR deficient HR deficient HR deficient HR deficient 
  
 
*0 = No mutation 
  1 = Mutation 
 
**The continuous CIN measurements were divided into tertiles (Low, Medium, High) and this information was added next to each CIN value to 
demonstrate the level of CIN for each sample in comparison to the whole TNT study cohort (n=135).  
Supplementary Table S4. (A) P-values of Fisher's exact tests of the associations between the tested CIN-measurements (as categorical) and 
BRCA1/2 deficiency status (B) P-values of Wilcoxon and Kruskal-Wallis rank sum tests of the associations between the tested CIN-





(categorical) BRCA1/2 deficiency* HLAMP Shannon diversity BRCA1-like HRD 
HLAMP 0.029 N/A 2.48E-07 0.207 0.609 
PGA 0.744 6.43E-09 3.33E-06 0.009 0.778 
Shannon diversity 0.744 1.86E-07 N/A 0.419 0.773 
NtAI 0.086 0.198 0.343 0.003 0.006 
AiCNA 0.744 1.36E-05 0.006 0.004 0.773 
AbCNA 0.047 6.43E-09 2.28E-10 0.82 0.021 
CnLOH 0.744 0.089 0.184 0.025 0.773 
BRCA1-like 0.948 0.177 0.366 N/A 0.773 





(continuous) BRCA1/2 deficiency* HLAMP Shannon diversity BRCA1-like HRD 
PGA 0.548 7.48E-09 8.14E-07 5.04E-04 0.696 
Shannon diversity 0.543 7.48E-09 N/A 0.014 0.928 
NtAI 0.328 0.03 0.073 7.51E-05 0.002 
AiCNA 0.684 2.43E-07 0.002 0.003 0.265 
AbCNA 0.12 2.18E-08 1.82E-08 0.858 0.086 
CnLOH 0.622 0.043 0.023 0.001 0.265 
 
P-values were adjusted for multiple comparisons with the Benjamini-Hochberg method. 
* The assessment of BRCA1/2 deficiency included the comparison of three groups: the BRCA1/2 wild-type (n=75), the BRCA1/2 mutated (n=20) and the BRCA1 promoter 
methylated (n=19) cases. 
Supplementary Table S5. Characteristics of identified pathogenic germline variants in cancer predisposition associated genes. 
 
Patient Chr. Start End Ref Alt Variant type Exonic function Gene 
Annotation 
Transcript Nucleotide change 
AA 
change Clinical sign. 
TNT267 2 215595140 215595140 G A exonic stopgain BARD1 NM_001282549 exon4:c.C457T p.Q153X Pathogenic/ Likely pathogenic 
TNT115 17 59861775 59861775 - A exonic frameshift insertion BRIP1 NM_032043 exon11:c.1483dupT p.S495fs Pathogenic 




TNT72 1 45799121 45799121 G T exonic stopgain MUTYH NM_001128425 exon3:c.C312A p.Y104X Pathogenic 
TNT237 1 45797228 45797228 C T exonic nonsynonymous SNV MUTYH NM_001128425 exon13:c.G1187A p.G396D Pathogenic 
TNT167 17 56787218 56787218 A G splicing - RAD51C NM_058216 exon5:c.706-2A>G - Pathogenic/ Likely pathogenic 
TNT134 8 145739070 145739070 T - exonic frameshift deletion RECQL4 NM_004260 exon13:c.2085delA p.K695fs Pathogenic 






Supplementary Table S6. Odds ratios, associated 95% confidence intervals and p-values for interaction from the evaluation of ORR between the 
treatment arms among the patient subgroups of (A) NtAI, (B) AiCNA and (C) HLAMP. 
 
 
(A) NtAI  
 
Treatment NtAI tertile N Odds ratio 95% CI Pinteraction 
Docetaxel 
1st 19 1 - 
0.083 
2nd 20 0.43 0.10 – 1.81 
3rd 29 1.21 0.37 – 3.98 
Carboplatin 
1st 22 0.98 0.27 – 3.50 
2nd 24 2.03 0.59 – 6.93 





Treatment AiCNA tertile N Odds ratio 95% CI Pinteraction 
Docetaxel 
1st 20 1 - 
0.060 
2nd 24 1.17 0.32 – 4.19 
3rd 24 1.40 0.40 – 4.96 
Carboplatin 
1st 25 1.83 0.53 – 6.34 
2nd 21 3.79 1.03 – 13.91 











Treatment HLAMP tertile N Odds ratio 95% CI Pinteraction 
Docetaxel 
Quiet 24 1 - 
0.098 
Low 27 1.67 0.52 – 5.37 
High 17 1.01 0.26 – 3.96 
Carboplatin 
Quiet 25 3.09 0.95 – 10.08 
Low 20 0.81 0.21 – 3.10 
High 22 1.68 0.49 – 5.72 
 
P-values for interaction tests are based on a logistic regression model of response, with terms for CIN-measurement status, treatment arm and 
interaction. 
Supplementary Table S7. Comparison of the results of Objective Response Rate (ORR) and Progression Free Survival analysis in the TNT study 
cohort (n=135) and the TNT ER- subset (n=131). (A) Associations between the CIN-measurements and ORR in the TNT study cohort, (B) in the 
ER- subset. (C) Non-adjusted and adjusted interaction p-values of logistic regression analysis of the association between the CIN-





TNT study cohort (n=135) 
CIN 
measurement Subgroup ORR 
Carboplatin Docetaxel Total Fisher’s 
exact p No. % No. % No. % 
NtAI intermediate No 11 45.83 16 80.00 27 61.36 0.030 Yes 13 54.17 4 20.00 17 38.64 
AiCNA intermediate No 8 38.10 16 66.67 24 53.33 0.076 Yes 13 61.90 8 33.33 21 46.67 
CnLOH intermediate No 13 52.00 17 85.00 30 66.67 0.027 Yes 12 48.00 3 15.00 15 33.33 
















TNT ER- subset (n=131) 
CIN 
measurement Subgroup ORR 
Carboplatin Docetaxel Total Fisher’s 
exact p No. % No. % No. % 
NtAI intermediate No 11 47.83 16 80.00 27 62.79 0.056 Yes 12 52.17 4 20.00 16 37.21 
AiCNA intermediate No 8 60.00 16 66.67 24 54.55 0.128 Yes 12 40.00 8 33.33 20 45.45 
CnLOH intermediate No 13 52.00 17 85.00 30 66.67 0.027 Yes 12 48.00 3 15.00 15 33.33 





Objective Response Rate (ORR) 
CIN 
measurement 
TNT study cohort (n=135) TNT ER- subset (n=131) 
Pinteraction Padj,interaction Pinteraction Padj,interaction 
NtAI 0.083 0.016 0.083 0.018 





Progression Free Survival (PFS) 
CIN 
measurement 
TNT study cohort (n=135) TNT ER- subset (n=131) 
Pinteraction Padj,interaction Pinteraction Padj,interaction 
HLAMP 0.047 0.033 0.081 0.033 
AiCNA 0.027 0.125 0.034 0.106 
PGA 0.053 0.176 0.123 0.218 
 





measurements AiCna NtAI HRD score BRCA1-like CnLoH HLAMP AbCna PGA Shannon index 
AiCna N/A 0.00E+00 0.004 0.001 0.163 1.98E-10 6.41E-05 2.32E-12 1.90E-04 
NtAI 0.00E+00 N/A 1.35E-07 3.64E-06 1.31E-04 0.009 0.958 3.02E-04 0.006 
HRD score 0.004 1.35E-07 N/A 0.098 0.077 0.844 0.057 0.83 0.234 
BRCA1-like 0.001 3.64E-06 0.098 N/A 3.09E-05 0.01 0.37 5.53E-07 4.68E-05 
CnLoH 0.163 1.31E-04 0.077 3.09E-05 N/A 0.048 5.19E-06 0.507 0.084 
HLAMP 1.98E-10 0.009 0.844 0.01 0.048 N/A 4.90E-11 1.35E-14 8.02E-13 
AbCna 6.41E-05 0.958 0.057 0.37 5.19E-06 4.90E-11 N/A 1.37E-10 1.49E-10 
PGA 2.32E-12 3.02E-04 0.83 5.53E-07 0.507 1.35E-14 1.37E-10 N/A 2.01E-08 
Shannon index 1.90E-04 0.006 0.234 4.68E-05 0.084 8.02E-13 1.49E-10 2.01E-08 N/A 
  
The corresponding Spearman correlation coefficients are shown on supplementary Figure S5. 
Supplementary Table S9. Objective Response Rate (ORR) within the BRCA1/2 mutated subgroup.  
 
 
 Treatment arm  
Objective 
response 
Carboplatin Docetaxel Total 
No. % No. % No. % 
No 2 15.38 5 55.56 7 31.82 
Yes 11 84.62 4 44.44 15 68.18 
Total 13 100 9 100 22 100 
 
 
  
